EMBO announces today the selection of 28 young researchers as EMBO Young Investigators. Among them Guadalupe Sabio, who joins a network of 47 current and 417 past Young Investigators who represent some of the best up-and-coming group leaders in the life sciences in Europe and beyond.
“It is a pleasure to welcome these outstanding scientists to the EMBO community,” says EMBO Director Maria Leptin. “Between them, they carry out some of the most promising life science research that Europe has to offer, and we look forward to supporting them in their professional and scientific undertakings.”
Selection to the EMBO Young Investigator Programme is recognition of exceptional research and scientific potential. Through the programme, EMBO identifies and supports some of the best researchers under 40 years of age who are in the process of establishing their own laboratory.
During their three-year tenure, EMBO Young Investigators receive a range of benefits, including an award of 15,000 euros and possible additional funds to support the establishment of their first independent laboratories. The scientists also receive access to core facilities at the European Molecular Biology Laboratory in Heidelberg, Germany, and funding for themselves and their group members to attend conferences.
Guadalupe Sabio at her laboratoy at CNIC (Photo: Ivana Nikolić).
Though the CICERONE Program is open to Masters and advanced undergraduate students for extending their scientific training through hands-on experience of laboratory-based biomedical research during the summer recess. In addition to carrying out a supervised research project, the students also attend CNIC seminars.
The aim of the program is to give university students first-hand knowledge of biomedical research so that they can make more informed choices about the possibility of pursuing a scientific career.
For the 2017 call, we are offering two different research projects:
- Role of p38MAPK in metabolic diseases: Metabolic syndrome is a medical disorder defined by the co-occurrence of obesity, impaired glucose tolerance, dyslipidemia and hypertension. Stress activated protein kinases have been shown to control both obesity by itself and diabetes associated to obesity. These stress kinases are activated by several MAPK activated kinases (MKK). We want to investigate the role of MKK3 in this process and the molecular mechanism by which this kinase could affect diabetes.
- p38MAPK in heart phisiology: The p38 MAPK pathway transduces a variety of extracellular signals regulating cellular responses to stress, being implicated in cell proliferation, differentiation and apoptosis. Its implication in the development of human diseases it is being deeply studied. Four p38 MAPK family members have been identified: p38α, β, γ and δ.
Preliminary data from our laboratory show that these kinases may control cytokine production during acute and chronic inflammatory processes. Moreover, studies with genetically modified mice made in our laboratory confirm that p38MAPKs have a role in the development of the heart. Our main objective is to determine if the regulation of the p38MAPK signaling pathway could have beneficial effects in the cardiac response to exercise.